Abstract:Transcription factor specificity protein 1 (Sp1) and hypoxia-inducible factor 1 alpha (HIF1 alpha) serve vital roles in tumor growth and metastasis. The present study aimed to evaluate the impact of co-expression of Sp1 and HIF1a on the prognosis of patients with hepatocellular cancer (HCC) using The Cancer Genome Atlas (TCGA) database and to validate the association between the expression levels of Sp1/HIF1 alpha in HCC specimens and patient survival using immunohistochemical analysis. A total of 214 eligible patients with HCC from TCGA database were collected for the study. The expression profile of Sp1 and HIF1a were obtained from the TCGA RNAseq database. Clinicopathological characteristics, including age, height, weight, gender, race, ethnicity, family cancer history, serum a-fetoprotein (AFP), surgical procedures and TNM stage were collected. The Cox proportional hazards regression model and Kaplan-Meier curves were used to assess the relative factors. Receiver operating characteristic (ROC) curves for cancer-specific survival (CSS) prediction were plotted to compare the prediction ability of expression of Sp1 and HIF1a and their co-expression. The location and expression of Sp1 and HIF1a in the HCC tissues were detected by immunohistochemistry (IHC) to verify the association between these two genes and CSS. The results demonstrated that the expressions of Sp1 and HIF1a were significantly increased in the succumbed group (P=0.001), compared with the surviving group. The CSS rates were 60.1% at 3 years (1,067 days), 35.8% at 5 years (1,823 days) and 9.5% at 10 years (3,528 days). Multivariate Cox regression analysis demonstrated that only the high expression levels of Sp1 and HIF1 alpha (>= 2x10(3)) were independent predictors for cancer mortality, with P=0.001 and P=0.029, respectively. The area under the curve for the ROC was found to be higher using the combination testing for two genes (0.751) in predicting cancer mortality, compared to a single gene (0.632 for Sp1 and 0.717 for HIF1a). Based on the cutoff points for gene expression, patients were divided into 3 groups: G1 (both genes <2x10(3)), G2 (either gene >= 2x10(3)) and G3 (both genes >= 2x10(3)). The risk of cancer mortality increased with high expression of genes, and G3 exhibited a greater risk than G2 when compared with the G1 group (HR=5.420, 95% CI 2.767-10.616, P=0.001; HR=3.270, 95% CI 1.843-5.803, P=0.001). The IHC staining results indicated that patients who died of cancer presented with significantly higher expression levels of these genes compared with those that did not (P=0.001). In summary, high expression levels of Sp1 and HIF1a in HCC tissues were associated with poor prognosis; in particular, the co-expression of these two genes increased the risk of cancer mortality.

High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy

The Association of HMGB1 Expression with Clinicopathological Significance and Prognosis in Hepatocellular Carcinoma: a Meta-Analysis and Literature Review.

High‑mobility group box 1 has a prognostic role and contributes to epithelial mesenchymal transition in human hepatocellular carcinoma

The Comprehensive Role of High Mobility Group Box 1 (HMGB1) Protein in Different Tumors: A Pan-Cancer Analysis

High expression of HM13 correlates with poor prognosis in hepatocellular carcinoma

Expression and Clinical Significance of HMGB1 in Human Liver Cancer: Knockdown Inhibits Tumor Growth and Metastasis in Vitro and in Vivo.

Human leukocyte antigen-G and prognosis of liver transplantation in patients with hepatocellular carcinoma

Overexpression Of Hmga2 Promotes Metastasis And Impacts Survival Of Advanced Colorectal Cancers

Clinical Implication of the Relationship Between High Mobility Group Box-1 and Tumor Differentiation in Hepatocellular Carcinoma

The Effect of HMGB1 on the Clinicopathological and Prognostic Features of Cervical Cancer.

In-depth Characterization of the Biomarkers Based on Tumor-Infiltrated Immune Cells Reveals Implications for Diagnosis and Prognosis in Hepatocellular Carcinoma.

Increased Expression of HMGB1 is Associated with Poor Prognosis in Human Bladder Cancer

Significance of HMMR Overexpression in Hepatocellular Carcinoma

HMGA2 as a prognostic and immune biomarker in hepatocellular carcinoma: Comprehensive analysis of the HMG family and experiments validation

ABCC1 is a predictive biomarker for prognosis and therapy in hepatocellular carcinoma

High Mir-454-3p Expression Predicts Poor Prognosis in Hepatocellular Carcinoma

High expression of BBOX1 in paracancerous tissue is associated with poor prognosis in hepatocellular carcinoma patients

Prognostic value of members of the HSP70 family in Hepatocellular Carcinoma

Clinical Value of PPM1G Gene in Survival Prognosis and Immune Infiltration of Hepatocellular Carcinoma

The Impact of High Co-Expression of Sp1 and HIF1α on Prognosis of Patients with Hepatocellular Cancer

[The Expression and Significance of Heparanase and Nm23-H1 in Hepatocellular Carcinoma].